3-methoxy-6,7-dihydroisoquinolin-8(5H)-one | 56053-58-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-methoxy-6,7-dihydroisoquinolin-8(5H)-one
• 英文别名: 3-methoxy-6,7-dihydro-5H-isoquinolin-8-one；3-methoxy-6,7-dihydro-5H-isoquinolin-8-one
• CAS: 56053-58-8
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: VGLCUNJZYQLHRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methoxy-6,7-dihydroisoquinolin-8(5H)-one 以58%的产率得到
  参考文献：
  名称：

  CHORVAT R. J., J. ORG. CHEM., 1978, 43, NO 19, 3778-3780

  摘要：

  DOI：
• 作为产物：
  描述：

  3-hydroxy-6,7-dihydroisoquinolin-8(5H)-one 以71%的产率得到
  参考文献：
  名称：

  SCHROEDER E.; LEHMANN M.; BOETTCHER I., EUR. J. MED. CHEM.-CHIM. THER., 1979, 14, NO 6, 499-506 D2#105#; #99# #10+

  摘要：

  DOI：

文献信息

• HMG-CoA reductase inhibitors
  申请人：Stein Philip D.

  公开号：US20070249583A1

  公开（公告）日：2007-10-25

  Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis wherein A is chosen from B is chosen from wherein the variables R 1 to R 7 , m, n, are as defined herein. A method for treating the above diseases employing the above compounds is also provided.

  提供以下结构的化合物是HMG CoA还原酶抑制剂，因此在抑制胆固醇生物合成、调节血清脂质，例如降低LDL胆固醇和/或增加HDL胆固醇，以及治疗高脂蛋白血症和血脂异常、高胆固醇血症、高甘油三酯血症和动脉粥样硬化方面具有活性。 其中A选择自 B选择自 其中变量R1至R7，m，n， 如本文所定义。 还提供了一种利用上述化合物治疗上述疾病的方法。
• TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS
  申请人：Genzyme Corporation

  公开号：US20150158847A1

  公开（公告）日：2015-06-11

  Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

  Tropomyosin相关激酶抑制剂（Trk抑制剂）是治疗疾病的小分子化合物。Trk抑制剂可用作药物代理和药物组合物。Trk抑制剂在治疗炎症性疾病、自身免疫疾病、骨代谢缺陷和/或癌症方面非常有用，特别适用于骨关节炎（OA）、疼痛以及与OA相关的疼痛的治疗。Trk抑制剂还可用于抑制与肌浆蛋白相关的激酶A（TrkA）、与肌浆蛋白相关的激酶B（TrkB）、与肌浆蛋白相关的激酶C（TrkC）和/或c-FMS（促红细胞生成因子-1（CSF-1）的细胞受体）有关的作用。
• HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS
  申请人：Burchat Andrew

  公开号：US20140162985A1

  公开（公告）日：2014-06-12

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供了化合物(I)的药用可接受盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此定义。本发明的化合物可用于治疗免疫和肿瘤疾病。
• Tropomyosin-related kinase (TRK) inhibitors
  申请人：Genzyme Corporation

  公开号：US09067914B1

  公开（公告）日：2015-06-30

  Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

  Tropomyosin-related kinase inhibitors (Trk抑制剂)是一种小分子化合物，可用于治疗疾病。Trk抑制剂可作为药物剂量和药物组成部分使用。Trk抑制剂在治疗炎症性疾病、自身免疫疾病、骨代谢缺陷和/或癌症方面非常有用，尤其在治疗骨关节炎（OA）、疼痛以及与OA相关的疼痛方面特别有用。Trk抑制剂还可用于抑制与肿瘤相关的蛋白激酶A、B、C和/或c-FMS（促红细胞生成素-1（CSF-1）的细胞受体）。
• Tropomyosin-related kinase (Trk) inhibitors
  申请人：Genzyme Corporation

  公开号：US09174986B2

  公开（公告）日：2015-11-03

  Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

  Tropomyosin-related kinase抑制剂（Trk抑制剂）是治疗疾病的小分子化合物。Trk抑制剂可用作制药剂和制药组合物。Trk抑制剂对治疗炎症性疾病、自身免疫疾病、骨代谢缺陷和/或癌症有用，尤其对于治疗骨关节炎（OA）、疼痛和与OA相关的疼痛特别有用。Trk抑制剂还可用于抑制肌动蛋白相关激酶A（TrkA）、肌动蛋白相关激酶B（TrkB）、肌动蛋白相关激酶C（TrkC）和/或c-FMS（集落刺激因子-1（CSF-1）的细胞受体）。